AACR conference examines how societal framework of racism drives cancer disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The global coronavirus pandemic has torn the veil that dimmed the nation’s awareness of the breadth and depth of health disparities, including cancer health disparities.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Steven R. Patierno, PhD
Deputy director, Duke Cancer Institute; Professor of medicine, pharmacology and cancer biology, professor of family medicine and community health, Duke University School Medicine; Conference co-chair, AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
Steven R. Patierno, PhD
Deputy director, Duke Cancer Institute; Professor of medicine, pharmacology and cancer biology, professor of family medicine and community health, Duke University School Medicine; Conference co-chair, AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login